

Ahmad, L; Mashbat, B; Leung, C; Brookes, C; Hamad, S; Krokowski, S; Shenoy, AR; Lorenzo, L; Levin, M; O'Hare, P; Zhang, SY; Casanova, JL; Mostowy, S; Sancho-Shimizu, V (2018) Human TBK1 is required for early autophagy induction upon HSV1 infection. The Journal of allergy and clinical immunology. ISSN 0091-6749 DOI: https://doi.org/10.1016/j.jaci.2018.09.03

Downloaded from: http://researchonline.lshtm.ac.uk/4649641/

DOI: 10.1016/j.jaci.2018.09.013

Usage Guidelines

 $Please\ refer\ to\ usage\ guidelines\ at\ http://research on line.lshtm.ac.uk/policies.html\ or\ alternatively\ contact\ research on line@lshtm.ac.uk.$

Available under license: http://creativecommons.org/licenses/by/2.5/

Accepted Manuscript

Human TBK1 is required for early autophagy induction upon HSV1 infection

Liyana Ahmad, PhD, Bayarchimeg Mashbat, PhD, Corwin Leung, MSc, Charlotte Brookes, MSc, Samar Hamad, MSc, Sina Krokowski, MSc, Avinash R. Shenoy, PhD, Lazaro Lorenzo, PhD, Michael Levin, MD, PhD, Peter O'Hare, PhD, Shen-Ying Zhang, MD, PhD, Jean-Laurent Casanova, MD, PhD, Serge Mostowy, PhD, Vanessa Sancho-Shimizu, PhD



PII: S0091-6749(18)31364-2

DOI: 10.1016/j.jaci.2018.09.013

Reference: YMAI 13644

To appear in: Journal of Allergy and Clinical Immunology

Received Date: 13 November 2017

Revised Date: 28 August 2018

Accepted Date: 7 September 2018

Please cite this article as: Ahmad L, Mashbat B, Leung C, Brookes C, Hamad S, Krokowski S, Shenoy AR, Lorenzo L, Levin M, O'Hare P, Zhang S-Y, Casanova J-L, Mostowy S, Sancho-Shimizu V, Human TBK1 is required for early autophagy induction upon HSV1 infection, *Journal of Allergy and Clinical Immunology* (2018), doi: https://doi.org/10.1016/j.jaci.2018.09.013.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1	Н	uman TBK1 is required for early autophagy induction upon HSV1 infection
2		
3	Liyana Ahma	d, PhD ^a ; Bayarchimeg Mashbat, PhD ^b ; Corwin Leung, MSc ^a ; Charlotte Brookes, MSc ^a ; Samar
4	Hamad, MSc ^a	; Sina Krokowski, $MSc^{c,d}$; Avinash R. Shenoy, PhD^e , Lazaro Lorenzo, $PhD^{f,g}$; Michael Levin,
5	MD, PhD ^b ; P	eter O'Hare, PhD ^a ; Shen-Ying Zhang, MD, PhD ^{f,g,h} ; Jean-Laurent Casanova, MD, PhD ^{f,g,h,i,j} ;
6	Serge Mostow	vy, PhD ^{c,d} ; Vanessa Sancho-Shimizu, PhD ^{a,b*}
7		
8	^a Department of V	Yirology, Division of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK
9	^b Department of P	aediatrics, Division of Medicine, Imperial College London, Norfolk Place, London, W2 1PG, UK
10	^c MRC Centre of I	Molecular Bacteriology and Infection (CMBI), Imperial College London, London, SW7 2AZ, UK
11	^d Department of In	mmunology and Infection, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK
12	^e Section of Micro	obiology, Medical Research Council Centre for Molecular Bacteriology and Infection, Imperial College London, London
13	SW7 2AZ, UK.	
14	^f Laboratory of Hu	uman Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France
15	^g University Paris	Descartes, Imagine Institute, Paris, France
16	^h St. Giles Labora	tory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
17	ⁱ Howard Hughes	Medical Institute, New York, NY, USA
18	^j Pediatric Hemato	ology and Immunology Unit, Necker Hospital for Sick Children, Paris, France
19		
20	*Corresponding	ng author:
21	Email:	v.sancho-shimizu@imperial.ac.uk
22	Telephone:	+44 02075943914
23	Address:	Department of Paediatrics, Division of Medicine, Imperial College London, Norfolk Place,
24		London, W2 1PG, UK
25		
26	Keywords:	Autophagy, HSV1, TBK1, TLR, IFN
27		
28		

To the Editor:

Mutations disrupting the Toll-like receptor 3 (TLR3)-dependent-interferon (IFN) pathway can underlie herpes simplex encephalitis (HSE) of childhood caused by herpes simplex virus-1 (HSV1) infection. These otherwise healthy HSE patients carry germline mutations in the TLR3-IFN circuit including *TRIF* and *TBK1*^{1, 2}. Their dermal fibroblasts show impaired IFN production following HSV1 infection and poly(I:C) stimulation. A number of these genes (*TLR3*, *TRIF*, *TBK1*) have also been implicated in the process of autophagy. On the other hand, HSV1 is known to antagonize the antiviral IFN pathway and the autophagy machinery in part via TBK1. Specifically, TBK1 is targeted by the viral encoded proteins ICP34.5, ICP27, VP24 and UL46, compromising anti-viral IFN signalling^{3, 4}. In the context of autophagy, TBK1 has been reported to phosphorylate autophagy receptors such as p62 to promote clearance of intracellular pathogens including HSV1 *in vitro*⁵. Herein, we study the role of autophagy in HSV1 infection using dermal fibroblasts from control and HSE patients with autosomal dominant (AD) TBK1 (p.G159A/WT) and autosomal recessive TRIF (p.R141X/R141X) deficiencies.

Despite showing normal autophagy activation after rapamycin and poly(I:C) stimulation, TBK1+/fibroblasts showed no induction of autophagy following multiple stimuli: cyclic di-guanylate monophosphate (c-di-GMP), HSV1 60mer-dsDNA (60mer-dsDNA), and HSV1 infection. Following rapamycin, LC3B punctate signal increased by 3-fold in both control (media: 20.0%, rapamycin: 72.3%) and TRIF- (media: 21.8%, rapamycin: 70.0%) fibroblasts, and by 6-fold (media: 11.0%, rapamycin: 61.1%) in TBK1^{+/-} fibroblasts, suggesting that TRIF and TBK1 were not required for rapamycin-induced autophagy (Fig 1, A and B). To assess autophagy induced via TLR3, poly(I:C) was used to stimulate fibroblasts leading to a 12-fold (media: 7.1%, poly(I:C): 86.5%) increase of LC3B puncta in control fibroblasts. TRIF- fibroblasts were unable to induce LC3B puncta, implicating TRIF in poly(I:C)-induced autophagy. TBK1+/- fibroblasts however showed a moderate 8-fold (media: 4.0%, poly(I:C): 31.3%) induction of autophagy suggesting its partial role in poly(I:C)induced autophagy consistent with its partial impairment of poly(I:C)-induced IFN production (Fig 1, A and C)². Although the role of dsRNA-TLR3 pathway in regulating autophagy has been documented in other cell lines, its involvement in infection remains elusive. In addition to TLR3-IFN signaling, TBK1 is also involved in the HSV1 DNA recognition pathway via STING-TBK1-IRF3 which serves to activate type I IFNs, and STINGdependent autophagy^{6, 7}. To evaluate induction of autophagy via this pathway, fibroblasts were transfected with c-di-GMP and 60mer-dsDNA, known to stimulate STING-induced autophagy and IFN production^{6, 7}. Whilst

mock treated fibroblasts did not show significant LC3B induction, we observed a 2-fold (c-di-GMP control: 20.7%, c-di-GMP: 45.2%) and 1.8-fold (c-di-GMP control: 18.5%, c-di-GMP: 33.6%) increase in punctate LC3B in control and TRIF^{-/-} fibroblasts respectively when transfected with c-di-GMP, compared to the c-di-GMP control. Significant induction of LC3B puncta following 60mer-dsDNA transfection was also observed in control and TRIF^{-/-} fibroblasts by 4-fold (media: 19.6%, 60mer-dsDNA: 84.8%) and 2-fold (media: 28.0%, 60mer-dsDNA: 67.6%) respectively. However, c-di-GMP and 60mer-dsDNA stimulation failed to induce LC3B puncta in TBK1^{+/-} fibroblasts (Fig 1, *A*, *D* and *E*) suggesting TBK1 is essential for dsDNA-induced autophagy.

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

59

60

61

62

63

64

65

In control fibroblasts, HSV1 infection triggered a 10-fold (non-infected: 0.2 a.u., infected MOI 5: 1.8 a.u.) increase in LC3BII:I and a 2-fold (non-infected: 1.0 a.u., infected MOI 5: 0.5 a.u.) reduction in p62 protein indicating activation of autophagy, as assessed by western blot (Fig 1, F). TRIF^{-/-} fibroblasts also showed a 6fold (non-infected: 0.2 a.u., infected MOI 5: 1.2 a.u.) LC3BII:I increase following infection at MOI 5. TBK1+/fibroblasts however showed no change in LC3BII:I or p62 following HSV1 infection suggesting impaired HSV1-induced autophagy. Depletion of endogenous TBK1 using siRNA in control fibroblasts recapitulated this impairment (Fig 1, G). Using immunofluorescence imaging, we found that HSV1 infection triggers two LC3B phenotypes in control fibroblasts: perinuclear LC3B puncta in infected cells and cytoplasmic LC3B puncta in antigen-negative-plaque-neighbouring ('antigen-negative') cells (Fig 2, A). Whilst the former occurs later in infection and is likely the phenomenon termed nuclear develop-derived autophagy (NEDA) as it also stained with LC3A⁸ (Fig 2, A), cytoplasmic LC3B formed early in infection (up to 3 hours post-infection) (Fig 2, B). Strikingly, TBK1^{+/-} fibroblasts failed to form cytoplasmic LC3B puncta in antigen-negative cells, despite being able to form perinuclear LC3B later in infection (Fig 2, A and B). Furthermore, inhibiting TBK1 in control fibroblasts using BX795 resulted in significant reduction in cytoplasmic LC3B formation (see Fig E1 in this article's Online Repository at www.jacionline.org). Whilst the lack of early autophagic induction was specific to TBK1^{+/-} fibroblasts, TRIF^{-/-} fibroblasts only showed delayed induction of autophagy (see Fig E2 in this article's Online Repository at www.jacionline.org), suggesting its partial involvement in HSV1-induced autophagy. The antigen-negative LC3B puncta has been previously reported in HSV1-infected mice trigeminal neurons but was shown to be cGAMP-independent and IFN-dependent⁹. In contrast to this, we find this phenomenon to be TBK1-dependent and IFNβ-independent since TRIF^{-/-} fibroblasts, shown to have undetectable IRF3 phosphorylation and IFNs after HSV1 infection¹ (see Fig E3, A and E4 in this article's Online Repository at www.jacionline.org), were able to induce this phenotype. Furthermore, IFN treatment was able to induce

autophagy in TBK1^{+/-} fibroblasts, ruling out the role of IFN in inducing cytoplasmic LC3B puncta in HSV1 infection (see Fig E5 in this article's Online Repository at www.jacionline.org). TBK1^{+/-} fibroblasts also failed to reduce STING following HSV1 infection in contrast to control and TRIF^{-/-} fibroblasts suggesting HSV1 induction is STING dependent (see Fig E3, *B*). We confirmed similar HSV1-induced autophagy phenotypes in primary fibroblasts from which these SV40-immortalized cell lines were derived from (see Fig E6 in this article's Online Repository at www.jacionline.org). These results show that the two types of autophagy differ in localization (cytoplasmic vs perinuclear) and temporal response to HSV1 infection, implying that they have different functions. We decided to focus on the TBK1-dependent early cytoplasmic phenotype as the later perinuclear LC3B, likely NEDA, was induced in all cells and has been reported to be a generalized stress response to viral late protein production⁸.

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

89

90

91

92

93

94

95

96

97

98

We next sought to understand how the different triggers of autophagy affect HSV1 infection. Following pre-treatment with poly(I:C), HSV1 replication was significantly reduced in control fibroblasts which can be attributed to the production of IFN_B (Fig 2, C and D). Consistently, with a low dose of HSV1, no viral plaque was observed in control fibroblasts which exhibited cytoplasmic puncta in response to the poly(I:C) treatment (Fig 2, C, D, E and G). Interestingly, poly(I:C)-induced LC3B puncta in TBK1+/- fibroblasts was detectable following HSV1 infection. This pre-enhanced autophagy and IFNβ production in TBK1^{+/-} fibroblasts however did not improve cell viability or viral replication in contrast to control fibroblasts (Fig 2, C-G). TRIF fibroblasts failed to induce autophagy or IFNs following poly(I:C) treatment1 and hence were not protected against HSV1 infection (Fig 2, D). Notably however, cytoplasmic LC3B puncta was present upon HSV1 infection of TRIF-¹ fibroblasts, confirming that the formation of cytoplasmic LC3B puncta is IFN-independent (Fig 2, C, D and G, Fig E3, A and E4). Rapamycin pre-treatment led to the induction of autophagy in control, TRIF^{-/-} and TBK1^{+/-} fibroblasts as expected (Fig 2, C and G). In control and TRIF^{-/-} fibroblasts, upregulating autophagy using rapamycin prior to HSV1 infection resulted in the same proportion of cytoplasmic LC3B puncta post-infection (non-treated infected vs rapamycin infected) (Fig 2, C and G). In contrast, rapamycin pretreated TBK1^{+/-} fibroblasts showed a 4-fold (non-treated infected: 8.7% vs rapamycin-infected: 35.5%) increase of cytoplasmic LC3B puncta in antigen-negative fibroblasts following HSV1 infection (Fig 2, C and G). Rapamycin pretreatment did not affect viral replication in all cells however it significantly improved cell viability of TBK1^{+/-} cells (non-treated: 55.0% vs rapamycin treated: 76.7%) (Fig 2, E, F and G). Taken together, this shows that rapamycin-induced autophagy selectively increased the number of cytoplasmic LC3B, which

119	confers a cytoprotective effect by increasing cell viability in TBK1+/- fibroblasts. This protective effect of
120	rapamycin could not be attributed to IFN β as rapamycin did not induce IFN β (Fig 2, D).
121	
122	In conclusion, we show that in addition to its antiviral role in IFN production via TLR3 and STING ^{1, 2,}
123	⁶ , TBK1 induces autophagy upon HSV1 infection. We demonstrate that TBK1-induced autophagy occurs early
124	during HSV1 infection in antigen-negative fibroblasts, can be mediated by c-di-GMP or HSV1 dsDNA and is
125	TLR3- and IFN-independent. TBK1+/- fibroblasts derived from a HSE patient harboring a dominant negative
126	mutation had a selective impairment of autophagy induction early in infection represented by the lack of
127	cytoplasmic LC3B puncta formation. We believe that host or viral induced factors, possibly acting as danger
128	signals, can trigger autophagy in antigen-negative fibroblasts promoting cell survival without influencing viral
129	replication. This study highlights a possibly cytoprotective role for TBK1 in HSV1-induced autophagy which
130	may serve to control inflammation and has potential implications for patients with HSE.
131	
132	Liyana Ahmad, PhD ^a
133	Bayarchimeg Mashbat, PhD ^b
134	Corwin Leung, MSc ^a
135	Charlotte Brookes, MSc ^a
136	Samar Hamad, MSc ^a
137	Sina Krokowski, MSc ^{c,d}
138	Avinash R. Shenoy, PhD ^e
139	Lazaro Lorenzo, MSc ^{f,g} ,
140	Michael Levin, MD PhD ^b
141	Peter O'Hare, PhD ^a
142	Shen-Ying Zhang, MD, PhD ^{f,g,h}
143	Jean-Laurent Casanova, MD, PhD ^{f,g,h,i,j}
144	Serge Mostowy,PhD ^{c,d}
145	Vanessa Sancho-Shimizu, PhD ^{a,b*}
146	
147	From ^a Department of Virology, Division of Medicine, Imperial College London, Norfolk Place, London W2


148


From ^aDepartment of Virology, Division of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK; ^bDepartment of Paediatrics, Division of Medicine, Imperial College London, Norfolk Place, London

149	W2 1P	G, UK; ^c MRC Centre of Molecular Bacteriology and Infection (CMBI), Imperial College London,
150	London	, SW7 2AZ, UK; ^d Department of Immunology and Infection, London School of Hygiene and Tropical
151	Medicii	ne, London, WC1E 7HT, UK; ^e Section of Microbiology, Medical Research Council Centre for Molecular
152	Bacterio	ology and Infection, Imperial College London, London, SW7 2AZ, UK; ^f Laboratory of Human Genetics
153	of Infec	ctious Diseases, Necker Branch, INSERM U1163, Paris, France; gUniversity Paris Descartes, Imagine
154	Institute	e, Paris, France; ^h St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch,
155	The Ro	ckefeller University, New York, NY, USA; ⁱ Howard Hughes Medical Institute, New York, NY, USA;
156	^j Pediatr	ic Hematology and Immunology Unit, Necker Hospital for Sick Children, Paris, France.
157		
158	*Corres	pondence: v.sancho-shimizu@imperial.ac.uk
159	LA was	s supported by the Chancellor's scholarship of Universiti Brunei Darussalam, VSS is a Medical Research
160	Founda	tion fellow and the work described has been supported by this grant.
161		
162	REFE	RENCES
163	1.	Sancho-Shimizu V, Pérez de Diego R, Lorenzo L, Halwani R, Alangari A, Israelsson E, et al. Herpes
164		simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest
165		2011; 121:4889–902.
166	2.	Herman M, Ciancanelli M, Ou Y-H, Lorenzo L, Klaudel-Dreszler M, Pauwels E, et al. Heterozygous
167		TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp
168		Med 2012; 209:1567–82.
169	3.	Verpooten D, Yijie M, Hou S, Yan Z, He B. Control of TANK-binding kinase 1-mediated signaling by
170		the gamma(1)34.5 protein of herpes simplex virus 1. J Biol Chem 2009; 284:1097-105.
171	4.	Zheng C. Evasion of Cytosolic DNA-Stimulated Innate Immune Responses by HSV-1. J Virol 2018.
172	5.	Sparrer KMJ, Gableske S, Zurenski MA, Parker ZM, Full F, Baumgart GJ, et al. TRIM23 mediates
173		virus-induced autophagy via activation of TBK1. Nat Microbiol 2017; 2:1543-57.
174	6.	Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, et al. STING is a direct
175		innate immune sensor of cyclic di-GMP. Nature 2011; 478:515–8.
176	7.	Rasmussen SB, Horan KA, Holm CK, Stranks AJ, Mettenleiter TC, Simon AK, et al. Activation of
177		autophagy by alpha-herpesviruses in myeloid cells is mediated by cytoplasmic viral DNA through a
178		mechanism dependent on stimulator of IFN genes. J Immunol 2011; 187:5268-76.

-		ACCELLED MANUSCRILL
179	8.	Radtke K, English L, Rondeau C, Leib D, Lippe R, Desjardins M. Inhibition of the host translation
180		shutoff response by herpes simplex virus 1 triggers nuclear envelope-derived autophagy. J Virol 2013;
181		87:3990–7.
182	9.	Katzenell S, Leib DA. Herpes Simplex Virus and Interferon Signaling Induce Novel Autophagic
183		Clusters in Sensory Neurons. J Virol. 2016; 90:4706–19.
184		
185	FIGUR	RE LEGENDS
186	FIG 1	. TBK1 ^{+/-} fibroblasts show impaired cytosolic-dsDNA- and HSV1-induced autophagy. (A)
187	Immun	ofluorescence images of LC3B puncta (green) and DAPI (blue) in fibroblasts. Quantification of LC3B
188	puncta	positive fibroblasts stimulated with (B) rapamycin, (C) poly(I:C), (D) cdi-GMP or cdi-GMP control, and
189	(E) 60r	ner-dsDNA. (F) Immunoblots and densitometric graphs of HSV1-infected fibroblasts. (G) Immunoblot
190	confirm	ning TBK1 siRNA knockdown in control fibroblasts; immunoblots for LC3B, p62, GAPDH in HSV1-
191	infected	1 TBK1 knockdown fibroblasts. Viral titre and immunofluorescence images of infected TBK1
192	knockd	own fibroblasts. L; Lipofectamine, (all experiments were performed at least three times; means \pm SEM;
193	****P	<0.0001, *** $P < 0.001$ and * $P < 0.05$).
194		
195	FIG 2.	$TBK1^{\tiny +/-} \ fibroblasts \ lack \ cytoplasmic \ LC3B \ puncta \ induced \ early \ in \ HSV1 \ infection. \ (A,\ B,\ C)$
196	Immun	ofluorescence images of fibroblasts stained for HSV1 ICP4 (red), LC3B or LC3A (green), and DAPI
197	(blue).	White arrows indicate cytoplasmic LC3B, yellow arrows indicate perinuclear LC3A/B. Dashed lines
198	mark th	ne plaque boundary. (D) IFN\$\beta\$ production, (E) viral titre, (F) cell viability and (G) cytoplasmic LC3B
199	puncta	positive fibroblasts were quantified. n.d., not-detectable, (n=3; means ± SEM; ****P <0.0001, ***P
200	<0.001,	** $P < 0.01$ and * $P < 0.05$).

FIGURE 1





1	Legends for Online Repository Figures
2	
3	Fig E1 - TBK1 inhibition reduced cytoplasmic LC3B puncta formation but did not
4	affect perinuclear LC3B formation following HSV1 infection (A) Control and TBK1+/-
5	fibroblasts were pre-treated with 1 μM of BX795 for 16 hours before infecting with HSV1
6	(MOI 10) for indicated length of time, and being fixed and stained for LC3B (green) and/or
7	ICP4 (red). DAPI (blue) was used the nuclear stain. The scale bar of each representative
8	image is $20~\mu m$. Inset represents the magnified view of the indicated area and has a scale bar
9	of 10 μm . White arrows indicate cytoplasmic LC3B, while yellow arrows indicate perinuclear
10	LC3B. (B) The percentage of cells positive for cytoplasmic LC3B puncta in (A) was counted
11	on a minimum number of >100 cells. Images are representative of three independent
12	experiments (n=3). Data are represented as mean \pm SEM and were analysed by two-way
13	ANOVA; ** <i>P</i> <0.01.
14	
15	Fig E2 - TRIF ^{-/-} fibroblasts showed delayed cytoplasmic LC3B puncta formation – (A)
16	Fibroblasts grown on coverslips were infected with HSV1 (MOI 10) for indicated lengths of
17	time before being fixed and stained for endogenous LC3B (green) and/or HSV1 ICP4 (red)
18	proteins. DAPI (blue) was used as the nuclear stain. The scale bar of each representative
19	image is $20\ \mu m$. Inset represents the magnified view of the indicated area and has a scale bar
20	of 10 μm . White arrows indicate cytoplasmic LC3B, while yellow arrows indicate perinuclear
21	LC3B. (B) The percentage of cells positive for cytoplasmic LC3B puncta in (A) was counted
22	on a minimum number of >100 cells. Images are representative of three independent
23	experiments (n=3). Data are represented as mean \pm SEM and were analysed by two-way
24	ANOVA; ***P<0.001 and ****P<0.0001.
25	
26	Fig E3 – Endogenous protein levels of TBK1, IRF3, phosphorylated IRF3 and STING
27	during HSV1 infection. Control, TRIF ^{-/-} and TBK1 ^{+/-} fibroblasts were infected with HSV1
28	(MOI 1) for indicated lengths of time. Whole-cell lysates were electrophoresed and probed

29	for endogenous (A) TBK1, IRF3 phosphorylated IRF3 and (B) STING proteins. GAPDH was
30	used a loading control. Relative level of STING to GAPDH was measured by densitometry.
31	
32	Fig E4 – $TRIF^{-/-}$ and $TBK1^{+/-}$ fibroblasts showed impaired IFN β production following
33	HSV1 infection. Control, TRIF-/- and TBK1+/- fibroblasts were infected with HSV1 at
34	indicated MOIs for 24 hours before collecting supernatants and measuring IFN β by ELISA.
35	Data are represented as mean \pm SEM and were analysed by two-way ANOVA; n=3; * P <0.05
36	and **** <i>P</i> <0.0001.
37	
38	Fig E5 - IFN-induced autophagy in fibroblasts (A) Control, TRIF ^{-/-} and TBK1 ^{+/-} fibroblasts
39	were stimulated with $1X10^5\ IU/mL$ of IFN α -2A for 24 hours before being fixed and stained
40	for endogenous LC3B (green). DAPI (blue) was used as the nuclear stain. The scale bar of
41	each representative image is $20~\mu m$. Inset represents the magnified view of the indicated area
42	and has a scale bar of 10 $\mu m.$ White arrows indicate LC3B puncta. Images are representative
43	of three independent experiments (n=3)
44	
45	Figure E6 - Primary fibroblasts showed similar HSV1-induced autophagy phenotypes to
46	SV40-transformed fibroblasts. Primary fibroblasts grown on coverslips were infected with
47	HSV1 (MOI 10) for 3 or 8 hours before being fixed and stained for endogenous LC3B (green)
48	and/or HSV1 ICP4 (red) proteins. DAPI (blue) was used as the nuclear stain. The scale bar of
49	each representative image is $20~\mu m$. Inset represents the magnified view of the indicated area
50	and has a scale bar of 10 $\mu m.$ White arrows indicate cytoplasmic LC3B, while yellow arrows
51	indicate perinuclear LC3B. Images are representative of three independent experiments
52	(n=3).

1	METHODS
2	
3	Cell lines
4	Human SV40-immortalized dermal fibroblasts from healthy control, TBK1+/- (p.G159A), TRIF-/-
5	patients ^{E1, E2} , and Vero (African green monkey kidney) cells were maintained in 5% CO ₂ incubator at
6	37°C in DMEM supplemented with 10% fetal bovine serum (FBS).
7	
8	Viral infection and quantification
9	Human fibroblasts were infected with HSV1-GFP (KOS strain with GFP-tagged capsid protein VP26)
10	or HSV1 (strain 17AR+) at various MOIs and timepoints for immunoblot and immunofluorescence
11	experiments. After 1 hour infection in DMEM supplemented with 2% FBS, the virus was removed and
12	new media added with 1% HSV1 human neutralizing antibody. Viral titres were determined by
13	infecting a confluent monolayer of Vero cells in a 12-well or 96-well plate, and performing plaque
14	assay on them or calculating the 50% end point (TCID ₅₀ /mL) ^{E3} .
15	
	Stimulation and treatments
16 17	Stimulation and treatments Fibroblasts cells were stimulated with 25 µg/mL of poly(I:C) (GE Healthcare), 10 nM of rapamycin
16	
16 17	Fibroblasts cells were stimulated with 25 $\mu g/mL$ of poly(I:C) (GE Healthcare), 10 nM of rapamycin
16 17 18	Fibroblasts cells were stimulated with 25 μ g/mL of poly(I:C) (GE Healthcare), 10 nM of rapamycin (Calbiochem) or $1X10^5$ IU/mL of IFN α -2A (PBL Assay Science) for 24 hours, or treated with 1μ M of
16 17 18 19 20	Fibroblasts cells were stimulated with 25 μ g/mL of poly(I:C) (GE Healthcare), 10 nM of rapamycin (Calbiochem) or $1X10^5$ IU/mL of IFN α -2A (PBL Assay Science) for 24 hours, or treated with 1μ M of TBK1 inhibitor BX795 ^{E4} (Sigma) for 16 hours, or transfected with 8 μ g/mL of c-di-GMP (Invivogen)
16 17 18 19	Fibroblasts cells were stimulated with 25 μ g/mL of poly(I:C) (GE Healthcare), 10 nM of rapamycin (Calbiochem) or $1X10^5$ IU/mL of IFN α -2A (PBL Assay Science) for 24 hours, or treated with 1μ M of TBK1 inhibitor BX795 ^{E4} (Sigma) for 16 hours, or transfected with 8 μ g/mL of c-di-GMP (Invivogen) or c-di-GMP control (Invivogen) for 2 hours, or 2 μ g/mL of HSV1 dsDNA (60mer sequence: 5'-
16 17 18 19 20 21	Fibroblasts cells were stimulated with 25 μ g/mL of poly(I:C) (GE Healthcare), 10 nM of rapamycin (Calbiochem) or $1X10^5$ IU/mL of IFN α -2A (PBL Assay Science) for 24 hours, or treated with 1μ M of TBK1 inhibitor BX795 ^{E4} (Sigma) for 16 hours, or transfected with 8 μ g/mL of c-di-GMP (Invivogen) or c-di-GMP control (Invivogen) for 2 hours, or 2 μ g/mL of HSV1 dsDNA (60mer sequence: 5'-TAAGACACGATGCGATAAAATCTGTTTGTAAAATTTATTAAGGGTACAAATTGCCCTAGC-
16 17 18 19 20 21	Fibroblasts cells were stimulated with 25 μ g/mL of poly(I:C) (GE Healthcare), 10 nM of rapamycin (Calbiochem) or $1X10^5$ IU/mL of IFN α -2A (PBL Assay Science) for 24 hours, or treated with 1μ M of TBK1 inhibitor BX795 ^{E4} (Sigma) for 16 hours, or transfected with 8 μ g/mL of c-di-GMP (Invivogen) or c-di-GMP control (Invivogen) for 2 hours, or 2 μ g/mL of HSV1 dsDNA (60mer sequence: 5'-TAAGACACGATGCGATAAAATCTGTTTGTAAAATTTATTAAGGGTACAAATTGCCCTAGC-3'; Integrated DNA Technology) for 3 hours. C-di-GMP, c-di-GMP control and HSV1 dsDNA were
16 17 18 19 20 21 22	Fibroblasts cells were stimulated with 25 μg/mL of poly(I:C) (GE Healthcare), 10 nM of rapamycin (Calbiochem) or 1X10 ⁵ IU/mL of IFNα-2A (PBL Assay Science) for 24 hours, or treated with 1μM of TBK1 inhibitor BX795 ^{E4} (Sigma) for 16 hours, or transfected with 8 μg/mL of c-di-GMP (Invivogen) or c-di-GMP control (Invivogen) for 2 hours, or 2 μg/mL of HSV1 dsDNA (60mer sequence: 5′-TAAGACACGATGCGATAAAATCTGTTTGTAAAATTTATTAAGGGTACAAATTGCCCTAGC-3′; Integrated DNA Technology) for 3 hours. C-di-GMP, c-di-GMP control and HSV1 dsDNA were delivered by Lipofectamine® 2000 (L) transfection. For pre-treatment experiments, fibroblast were
16 17 18 19 20 21 22 23	Fibroblasts cells were stimulated with 25 μg/mL of poly(I:C) (GE Healthcare), 10 nM of rapamycin (Calbiochem) or 1X10 ⁵ IU/mL of IFNα-2A (PBL Assay Science) for 24 hours, or treated with 1μM of TBK1 inhibitor BX795 ^{E4} (Sigma) for 16 hours, or transfected with 8 μg/mL of c-di-GMP (Invivogen) or c-di-GMP control (Invivogen) for 2 hours, or 2 μg/mL of HSV1 dsDNA (60mer sequence: 5′-TAAGACACGATGCGATAAAATCTGTTTGTAAAATTTATTAAGGGTACAAATTGCCCTAGC-3′; Integrated DNA Technology) for 3 hours. C-di-GMP, c-di-GMP control and HSV1 dsDNA were delivered by Lipofectamine® 2000 (L) transfection. For pre-treatment experiments, fibroblast were
16 17 18 19 20 21 22 23 24 25	Fibroblasts cells were stimulated with 25 μ g/mL of poly(I:C) (GE Healthcare), 10 nM of rapamycin (Calbiochem) or $1X10^5$ IU/mL of IFN α -2A (PBL Assay Science) for 24 hours, or treated with 1μ M of TBK1 inhibitor BX795 ^{E4} (Sigma) for 16 hours, or transfected with 8 μ g/mL of c-di-GMP (Invivogen) or c-di-GMP control (Invivogen) for 2 hours, or 2 μ g/mL of HSV1 dsDNA (60mer sequence: 5'-TAAGACACGATGCGATAAAATCTGTTTGTAAAATTTATTAAGGGTACAAATTGCCCTAGC-3'; Integrated DNA Technology) for 3 hours. C-di-GMP, c-di-GMP control and HSV1 dsDNA were delivered by Lipofectamine® 2000 (L) transfection. For pre-treatment experiments, fibroblast were incubated with either rapamycin or poly(I:C) for 16 hours before infecting with HSV1.
16 17 18 19 20 21 22 23 24 25	Fibroblasts cells were stimulated with 25 μg/mL of poly(I:C) (GE Healthcare), 10 nM of rapamycin (Calbiochem) or 1X10 ⁵ IU/mL of IFNα-2A (PBL Assay Science) for 24 hours, or treated with 1μM of TBK1 inhibitor BX795 ^{E4} (Sigma) for 16 hours, or transfected with 8 μg/mL of c-di-GMP (Invivogen) or c-di-GMP control (Invivogen) for 2 hours, or 2 μg/mL of HSV1 dsDNA (60mer sequence: 5′-TAAGACACGATGCGATAAAATCTGTTTGTAAAATTTATTAAGGGTACAAATTGCCCTAGC-3′; Integrated DNA Technology) for 3 hours. C-di-GMP, c-di-GMP control and HSV1 dsDNA were delivered by Lipofectamine® 2000 (L) transfection. For pre-treatment experiments, fibroblast were incubated with either rapamycin or poly(I:C) for 16 hours before infecting with HSV1.

30	Non-Radioactive Cell Proliferation Assay (MTS) kit (Promega) and performed as per manufacturer's
31	instructions. Cell viability was determined by normalizing to non-infected cells of each cell line.
32	
33	RNA interference
34	Cells were seeded in 10% FBS-supplemeted DMEM at 0.05X10 ⁶ cells/well in a flat-bottomed 24-well
35	plate and incubated for 18 hours in 37°C humidified incubator. Medium was then replaced with fresh
36	2% FBS-supplemented DMEM and cells were transfected with 15 nM of scramble (siNegative)
37	(Ambion) or pooled three TBK1-specific (siTBK1) small interfering RNAs (siRNAs) (siRNA ID no.
38	134003, 134002 & 899, Ambion) at 80% confluency using Lipofectamine® RNAiMAX vector (Life
39	Technologies) and incubated for further 48 hours in 37 °C incubator.
40	
41	Immunofluorescence and quantification of puncta-positive cells
42	Cells were grown at 50% confluency on 13 mm diameter coverslips and fixed with 100% methanol on
43	ice, before washing them with 1X phosphate buffered saline (PBS). Blocking was done in 10%-FBS
44	PBS and cells were permeabilized with 0.1% TritonX-100 in PBS. Staining was done in a moist
45	chamber using the following antibodies: LC3B (1:500 dilution, Abcam), cleaved LC3A (1:100
46	dilution, Stratech), HSV1 immediate early protein ICP4 (clone 10F1) (1:500 dilution, Virusys), Alexa
47	Fluor-488 and -594 conjugated secondary antibodies (1:750 and 1:1000 dilutions respectively, Life
48	Technologies). Images were taken with 63X oil-immersion lens on a widefield fluorescence
49	microscope (Zeiss Axio Observer). The number of LC3B puncta-positive cells was quantified on a
50	minimum number of 100 cells per experiment.
51	
52	Immunoblotting
53	Whole-cell lysates of fibroblasts infected with HSV1 for 48 hours were harvested in 1X Laemmli
54	buffer supplemented with protease inhibitor cocktail (Roche), 10% β-mercaptoethanol and 1:1000 of
55	benzonase nuclease (Sigma). Lysates were denatured and electrophoresed on 12% tris-glycine or 10%
56	bis-tris gels (Biorad). Proteins were transferred onto PVDF membrane (Invitrogen), probed with
57	primary and secondary horse-radish peroxidase (HRP)-conjugated antibodies (1:1000 and 1:10, 000
58	dilution respectively) and subsequently detected using enzyme-chemiluminescent reagents (GE
59	Healthcare). For LC3B immunoblots, bafilomycin A1 (Sigma) was added to culture medium for 6

60 hours prior to lysis for immunoblotting to block LC3BII recycling to LC3BI. The following antibodies 61 were used for immunoblotting: LC3B (Cell Signaling Technology), p62 (MBL International), TBK1 62 (Cell Signaling Technology), IRF3 (D83B9) (Cell Signaling Technology), IRF3-phospho (S396) (Cell 63 Signaling Technology), STING (D2P2F) (Cell Signaling Technology), and GAPDH-HRP (Santa Cruz 64 Biotech). GAPDH was used as a loading control. 65 66 **ELISA** 67 IFNβ secretion in recovered supernatants of cells pre-treated with rapamycin or poly(I:C) for 24 hours was measured using the VeriKine-HSTM human IFNβ serum ELISA kit (assay range: 1.2 – 150 pg/mL) 68 69 (PBL Assay Science) following the manufacturer's instructions. 70 71 Statistical analysis and software 72 Immunofluorescence images were analysed by Icy software. Densitometric analyses of immunoblots 73 were carried out using ImageJ. Statistical significance was assessed by two-way ANOVA using Prism 74 7 (Graphpad) software. Number of fluorescent cells or LC3B puncta-positive cells was quantified using 75 ImageJ software. All experiments were performed at least 3 times. 76 77 REFERENCES 78 E1. Sancho-Shimizu V, Pérez de Diego R, Lorenzo L, Halwani R, Alangari A, Israelsson E, et al. 79 Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J 80 Clin Invest 2011;121:4889–902. 81 E2. Herman M, Ciancanelli M, Ou Y-H, Lorenzo L, Klaudel-Dreszler M, Pauwels E, et al. 82 Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of 83 childhood. J Exp Med 2012;209:1567-82. 84 E3. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J 85 Hyg. 1938;27:493-497. 86 E4. Clark K, Plater L, Peggie M, Cohen P. Use of the pharmacological inhibitor BX795 to study the 87 regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase 88 mediates Ser-172 phosphorylation and activation. J Biol Chem. 2009;284:14136–46.

Fig E1




Fig E2






Fig E3








Fig E4




Fig E5




Fig E6

